Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632807 | 1.00 | LMNA (0.62) | LMNAMAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL196919 | 1.00 | LMNA (0.62) | LMNAMAPK1HDAC3HDAC4HDAC1 | |
| Fluoride SCHEMBL28879249 | 0.98 | LMNA (0.60) | LMNAMAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL8997409 | 0.94 | LMNA (0.56) | LMNAMAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL275597 | 0.87 | LMNA (0.79) | LMNAMAPK1NPSR1BLMTSHR | |
| SCHEMBL19735013 | 0.79 | HDAC3 (0.45) | LMNAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11218186 | 0.79 | HDAC3 (0.45) | LMNAMAPK1HDAC3HDAC4HDAC1 | |
| SCHEMBL4092644 | 0.79 | HDAC3 (0.45) | LMNAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL531658 | 0.79 | HDAC3 (0.45) | LMNAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28795451 | 0.79 | HPGD (0.48) | LMNAMAPK1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113355367-B | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2024-03-26 | — | — | CN | claimed |
| US-20220325035-A1 | POLYESTER, POLYESTERAMIDE, AND POLYAMIDE COMPOSITIONS | IYER ANANTH V (US) | 2022-10-13 | — | — | US | claimed |
| CN-113355299-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2022-05-24 | — | — | CN | claimed |
| CN-113355299-A | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | claimed |
| CN-113355367-A | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | claimed |
| CN-108410831-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-07-27 | — | — | CN | claimed |
| JP-11152247-A | — | — | None | — | — | JP | disclosed |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3898581-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| JP-H11152247-A | PRODUCTION OF PHENYLACETIC ACID DERIVATIVE | SUMIKA FINE CHEMICALS CO LTD | 1999-06-08 | — | — | JP | disclosed |
| EP-0838448-A1 | Process for the separation of a mixture of enantiomers | DSM N.V. (NL) | 1998-04-29 | — | — | EP | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-4218380-A | OXIDATION OF THE A-HYDROXY-ARYLACETIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | LMNA 2085/4885MAPK1 4366/4885HDAC3 1130/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | LMNA 1196/4885MAPK1 397/4885HDAC3 3027/4885 |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | KCNH2, KCNH3, KCNH1 | LMNA 1059/4885MAPK1 3023/4885HDAC3 183/4885 |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | LMNA 2085/4885MAPK1 4366/4885HDAC3 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.